After the treatments with antioxidant or iron chelation, the levels of ROS in the IO MDS group significantly decreased, with the downregulated β-catenin in gene and protein levels and the upregulated protein p-GSK-3β. Here, GSK3B is linked to myelodysplastic syndrome.